Abstracts tagged "Outcome measures"

Abstract Number: 2620 • ACR Convergence 2025
Transition Success of Pediatric Rheumatology Patients: A Novel Scoring System
Kyla Blasingame¹, David McDonald¹, Karissa Chesky¹, Jimin Kim¹, charles lee¹, Constance Wiemann¹, Blanca Sanchez-Fournier¹, Miriah Gillispie-Taylor² and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Success of transition from pediatric to adult care depends on many factors. Various scores for transition readiness have been developed, including some designed to…
Abstract Number: 2355 • ACR Convergence 2025
Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
KURT OELKE¹, Sarah Ross², Emily Edson-Heredia³, Jennifer Pustizzi⁴, Ali Sheikhi Mehrabadi⁵, Natalia Bello⁵, Frederick Murphy⁶, Shikha Singla⁷, Siba Raychaudhuri⁸, Philip J Mease⁹ and Arthur Kavanaugh¹⁰, ¹rheumatic disease center, Glendale, WI, ²Lilly, Indianapolis, IN, ³eli lilly, indianapolis, ⁴Eli Lilly, Hammonton, NJ, ⁵Eli Lilly, Indianapolis, IN, ⁶Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁷Medical College of Wisconsin, Milwaukee, WI, ⁸UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁹University of Washington, Seattle, WA, ¹⁰University of California, San Diego, School of Medicine, San Diego, CA

Background/Purpose: Ixekizumab (IXE) is an FDA-approved monoclonal antibody that targets interleukin-17A.Methods: Psoriatic Arthritis Real-World Study in the US (PARTUS) was a prospective, multicenter, non-interventional cohort…
Abstract Number: 2183 • ACR Convergence 2025
Bridging the Musculoskeletal Ultrasound Training Gap: Analysis of Confidence, Competency, and Clinical Readiness
Kamini Shah¹, Jonathan Samuels², Jennifer Medlin³, Philip Chu⁴, Midori Nishio⁵, Norman Madsen⁶, Michelene Hearth-Holmes³, Shivani Shah⁷, Catherine Bakewell⁸, Anthony M. Reginato⁹ and Minna Kohler¹⁰, ¹Northwell Health, New York, NY, ²NYU Langone, Rye Brook, NY, ³University of Nebraska Medical Center, Omaha, NE, ⁴Duke University Hospital, Raleigh, NC, ⁵John Muir Specialty Medical Group, Lafayette, CA, ⁶URMC, Rochester, NY, ⁷University of Chicago, New York, NY, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Brown University, Providence, RI, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While point-of care ultrasound (POCUS) training is increasingly introduced during rheumatology fellowship, limited exposure may not provide the depth or continuity needed to build…
Abstract Number: 1704 • ACR Convergence 2025
Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
William Soulsby¹, John Boscardin², Daniel Horton³, Andrea Knight⁴, Karine Toupin-April⁵ and Emily von Scheven², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Social determinants of health (SDOH) operate across individual, family, and community levels. We previously demonstrated that cumulative social disadvantage, comprised of individual and family-level…
Abstract Number: 1426 • ACR Convergence 2025
Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis
Pankti Mehta¹, Fadi Kharouf², Virginia Carrizo Abarza³, Shangyi Gao⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is the most commonly used tool to assess axial disease in psoriatic arthritis (PsA). However, five…
Abstract Number: 1115 • ACR Convergence 2025
Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Juliette quelain¹, Eleonore Mourre², Julien Henry¹, Rakiba Belkir³, Andrew Cope⁴, Debashis Sarker⁵, Yin Wu⁶, Matthaios Kapiris⁷, Aurelien Marabelle⁸, Caroline Robert⁸, Raphaele Seror⁹, Xavier Mariette¹⁰ and Samuel Bitoun¹, ¹APHP, PARIS, France, ²APHP, PARIS, ³PARIS, PARIS, France, ⁴King's College London, London, United Kingdom, ⁵Comprehensive Cancer Centre and Consultant Medical Oncologist at Guy's, St Thomas' and King's College Hospitals., London, United Kingdom, ⁶Honorary Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷KCL, LONDON, United Kingdom, ⁸IGR, PARIS, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France
Background/Purpose: Approvals for immune checkpoint inhibitors (ICIs) have expanded, and triple therapy combining anti-PD-1, anti-CTLA-4, and anti-LAG3 have been evaluated with encouraging results. But they…
Abstract Number: 0567 • ACR Convergence 2025
Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Atul Deodhar¹, Laure Gossec², Philip J. Mease³, Xenofon Baraliakos⁴, Lihi Eder⁵, Alan Kivitz⁶, Helena Marzo-Ortega⁷, Frank Behrens⁸, Ana-Maria Orbai⁹, Georg Schett¹⁰, Arthur Kavanaugh¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ⁸Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University of California, San Diego, School of Medicine, San Diego, CA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation.…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 0227 • ACR Convergence 2025
Malignancy Screening of Dermatomyositis Patients in the Penn State Registry of Inflammatory Myopathies (PRIMO)
Katrina Gonzales¹, William DeKryger², Deepika Pugalenthi Saravanan², Esha Tulsian², Peri Newman³, Jacob Colello², Galen Foulke⁴ and Nancy Olsen⁵, ¹Penn State College of Medicine, Hummelstown, PA, ²Penn State College of Medicine, Hershey, PA, ³Penn State Health/ Penn State College of Medicine, Hershey, PA, ⁴Penn State Health, Hershey, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is an immune-mediated myopathy characterized by muscle weakness and skin rash that carries an elevated risk of associated malignancy within 5 years…
Abstract Number: 2554 • ACR Convergence 2025
Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
Didem Saygin¹, Elizabeth Neal², Edward O'Bryan³, Alisha Smith, PharmD³, Leslie Myers³ and Timothy Walton³, ¹Rush University Medical Center, Chicago, IL, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Nash
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are autoimmune diseases typically characterized by muscle weakness. Intravenous Immunoglobulin (IVIg) is an effective immunomodulatory therapy in patients with refractory…
Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Francesco Fulvio Bizzarri¹, Luis Alberto Menchén Viso², Esther Chamorro De Vega³, Ofelia Baniandrés Rodríguez⁴ and Juan Carlos Nieto², ¹Hospital Universitario Clinico San Cecilio, Granada, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…
Abstract Number: 2142 • ACR Convergence 2025
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Hannah Concannon¹, Jasmine Oesch², Sara Mazzarelli², Anne Fields², Keisha-Gaye O'Garo² and Rebecca Sadun³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: The transition from pediatric to adult care can pose a challenge for patients with SLE and other rheumatic diseases. These patients often face preventable…
Abstract Number: 1685 • ACR Convergence 2025
The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
Raphaele Seror¹, Gabriel Baron², Elodie Perrodeau³, Alena Piatrova⁴, Hendrika Bootsma⁵, Simon Bowman⁶, Jacques-eric GOTTENBERG⁷, Divi Cornec⁸, michele Bombardieri⁹, Suzanne Arends¹⁰, Benjamin A. Fisher¹¹, Wolfgang Hueber¹², Antoine Sreih¹³, Antonia Christodoulou¹⁴, Andre van Maurik¹⁵, Joel van Roon¹⁶, Valerie Devauchelle¹⁷, Peter Gergely¹⁸, Xavier Mariette¹⁹ and Raphael Porcher²⁰, ¹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²Hôtel-Dieu, Université Paris Cité,, Paris, France, ³Université Paris Descartes Sorbonne Paris Cité, Paris, France, ⁴Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., Paris, Ile-de-France, France, ⁵UMCG, Groningen, Netherlands, ⁶University Hospitals Birmingham, Birmingham, United Kingdom, ⁷Hautepierre Hospital, STRASBOURG, Alsace, France, ⁸Departement of Rhumatology, CHU Brest, Université de Brest, INSERM UMR¹²²⁷: LBAI, Brest, France, Brest, France, ⁹Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ¹⁰University Medical Center Groningen, Groningen, Netherlands, ¹¹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹²Novartis Pharmaceuticals, Basel, Switzerland, ¹³Cullinan Therapeutics, New York, NY, ¹⁴BMS, Princeton, NJ, ¹⁵GlaxoSmithKline, Stevenage, United Kingdom, ¹⁶Center of Translational Immunology, Department of Immunology and Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht PO BOX ⁸⁵⁵⁰⁰, ³⁵⁰⁸ GA, Netherlands, Utrecht, Netherlands, ¹⁷UBO, Brest, France, ¹⁸Novartis Biomedical Research, Basel, Switzerland, ¹⁹Université Paris-Saclay, Le Kremlin Bicetre, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France
Background/Purpose: Performance of the recently developed composite responder index STAR is highly awaited. We conduscted this study to evaluate the performance of STAR in previously…
Abstract Number: 1411 • ACR Convergence 2025
Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
Conor Coyle¹, Sarah Yazji², Sruthi Murthy³, Philip Helliwell⁴, Andra Balanescu⁵, Juan Cañete⁶, Emmanuelle Dernis⁷, Uta Kiltz⁸, Ying Ying Leung⁹, Ana-Maria Orbai¹⁰, PENELOPE PALOMINOS¹¹, Josef Smolen¹², Maarten de Wit¹³, Laure Gossec¹⁴ and Laura Coates¹⁵, ¹Oxford University Hospitals, Reading, United Kingdom, ²South Texas Health System GME Consortium, Texas A&M College of Medicine, Texas, USA, College Station, TX, ³Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁶Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁷Rheumatology Department, Le Mans Central Hospital, Le Mans, France, LE MANS, France, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, Singapore, Singapore, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Hospital Lifeplus Litoral Norte, Xangri-lá, Brazil, Porto Alegre, Rio Grande do Sul, Brazil, ¹²Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ¹⁴Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ¹⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Treat to target management is recommended in psoriatic arthritis (PsA) to improve disease control and patient quality of life. Minimal disease activity (MDA) criteria…
Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Arthur Lau⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…

« Previous Page
1
…
6
7
8
9
10
…
59
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].